title: HIV-related neurocognitive impairment in the HAART era.
abstract: Neurocognitive impairment is common in people living with HIV and AIDS. Prior to highly active antiretroviral therapy (HAART), cognitive impairment primarily affected patients with advanced disease, and was a more rapidly progressive illness. With the use of HAART, cognitive impairment improved, along with the overall health of HIV-positive patients. However, it is still a prevalent problem, even in patients with desirable CD4+ count and undetectable plasma viral load. In this review, we address the nature of HIV-related neurocognitive impairment in the HAART era, including its etiology, pathology, appropriate diagnostic tools for clinical practice and research, and rational treatment approaches.
authors: Mount Sinai School of Medicine, Department of Neurology, Box 1052, One Gustave L. Levy Place, New York, NY 10029, USA. jessica.robinson-papp@mssm.edu
authors: Jessica
authors: J
authors: Robinson-Papp
authors: Kathryn J
authors: KJ
authors: Elliott
authors: David M
authors: DM
authors: Simpson
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D001521:Behavior Therapy; D015415:Biomarkers; D001921:Brain / Q000000981:diagnostic imaging; D003072:Cognition Disorders / Q000175:diagnosis* / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D009483:Neuropsychological Tests; D011859:Radiography
chemical_list: D015415:Biomarkers